Floatz logo

Buparlisib

PI3K Pathway Inhibition

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the PI3K Pathway Inhibition cohort.

Asset / SponsorPhaseRating
Alpelisib
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Buparlisib is also rated in:

breast cancerDormant
B
Indicative ·
58 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →